Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Polypills for cardiovascular prevention: a step forward?

The effect of a fixed-dose combination drug strategy ('polypill') on patients' adherence to medication was analysed in a series of 2,004 individuals with, or at high risk of, cardiovascular disease in the UMPIRE study. The polypill improved adherence by >20%, but the reduction in blood-pressure and cholesterol levels was modest.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918–929 (2013).

    Article  CAS  Google Scholar 

  2. Beaglehole, R. & Bonita, R. Global public health: a scorecard. Lancet 372, 1988–1996 (2008).

    Article  Google Scholar 

  3. Yusuf, S. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 378, 1231–1243 (2011).

    Article  Google Scholar 

  4. Mendis, S. et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull. World Health Organ. 85, 279–288 (2007).

    Article  Google Scholar 

  5. Chapman, R. H. et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 165, 1147–1152 (2005).

    Article  Google Scholar 

  6. Jansa, M. et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions: a cross-sectional study in a tertiary hospital. Patient Educ. Couns. 81, 161–168 (2010).

    Article  Google Scholar 

  7. Wald, N. J. & Law, M. R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419 (2003).

    Article  CAS  Google Scholar 

  8. Elley, C. R. et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS ONE 7, e52145 (2012).

    Article  CAS  Google Scholar 

  9. Sanz, G. & Fuster, V. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill. Mt Sinai J. Med. 79, 683–688 (2012).

    Article  Google Scholar 

  10. Sanz, G. et al. The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug: study design and objectives. Am. Heart J. 162, 811–817 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Valentin Fuster.

Ethics declarations

Competing interests

The authors declare no competing interests. G. Sanz and V. Fuster are involved in designing and trialling a polypill with Ferrer Internacional (Barcelona, Spain).

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanz, G., Fuster, V. Polypills for cardiovascular prevention: a step forward?. Nat Rev Cardiol 10, 683–684 (2013).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing